Incyte (INCY) Interest Expenses (2010 - 2026)
Incyte's (INCY) quarterly Interest Expenses came in at $6.3 million in Q2 2026, up 10.53% YoY from $5.7 million in Q2 2025, and down 1.56% on a QoQ basis from $6.4 million in Q1 2026.
Analysis
Incyte (INCY) Interest Expenses (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Interest Expenses data on file, last reported at $6.3 million in Q2 2026.
- Quarterly Interest Expenses rose 10.53% year-over-year to $6.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$1.6 million (down 107.35% YoY) and the FY2025 annual result came in at $22.4 million, down 98.95% from the prior year.
- Interest Expenses fell to $6.3 million in Q2 2026, from $6.4 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $6.4 million in Q1 2026 to a low of -$14.9 million in Q4 2025.
- A 5-year average of $2.7 million and a median of $5.0 million in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses plunged 1906.45% — and 2024, when it jumped 139.84%.
- Tracing INCY's Interest Expenses over 5 years: stood at $667000.0 in 2022, then sank by 1906.45% to -$12.0 million in 2023, then surged by 139.84% to $4.8 million in 2024, then sank by 409.83% to -$14.9 million in 2025, then surged by 142.36% to $6.3 million in 2026.
- The last three Interest Expenses figures came in at $6.3 million (Q2 2026), $6.4 million (Q1 2026), and -$14.9 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | 582,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 582,000.00 |
| Mar 31, 2026 | 569,000.00 |
| Dec 31, 2025 | 582,000.00 |
| Sep 30, 2025 | 592,000.00 |
| Jun 30, 2025 | 594,000.00 |
| Mar 31, 2025 | 660,000.00 |
| Dec 31, 2024 | 419,000.00 |
| Sep 30, 2024 | 774,000.00 |
| Jun 30, 2024 | 657,000.00 |
| Mar 31, 2024 | 430,000.00 |
| Dec 31, 2023 | 804,000.00 |
| Sep 30, 2023 | 623,000.00 |
| Jun 30, 2023 | 655,000.00 |
| Mar 31, 2023 | 469,000.00 |
| Dec 31, 2022 | 667,000.00 |
| Sep 30, 2022 | 641,000.00 |
| Jun 30, 2022 | 678,000.00 |
| Mar 31, 2022 | 680,000.00 |
| Dec 31, 2021 | 752,000.00 |
| Sep 30, 2021 | 439,000.00 |